CRONCronos Group Inc.

$983M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$25M+29.7% YoY

Gross Profit

$4M17.7% margin

Operating Income

-$16M-63.1% margin

Net Income

-$2M-8.9% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+5.7%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$36M

Stockholders' Equity

$1.1B

Cash & Equivalents

$855M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$19M	+29.7%
Gross Profit	$4M	$3M	+53.2%
Operating Income	-$16M	-$21M	+23.2%
Net Income	-$2M	-$19M	+88.3%

Revenue Segments

Cannabis Flower

$18M69%

Cannabis Extracts

$8M31%

Product and Service, Other

$36,0000%

Geographic Segments

CANADA

$19M75%

ISRAEL

$6M25%

CRON Q1 2024 Earnings — Cronos Group Inc. Revenue & Financial Results | Market Cap Arena